Zavaleta-Monestel Esteban, Rojas-Chinchilla Carolina, Campos-Hernández Jeimy, Martínez-Vargas Ernesto
Research, Hospital Clinica Biblica, San Jose, CRI.
Pharmacy, Hospital Clínica Bíblica, San José, CRI.
Cureus. 2025 Jan 31;17(1):e78296. doi: 10.7759/cureus.78296. eCollection 2025 Jan.
Antimicrobial resistance (AMR) is a growing public health issue, complicating the treatment of bacterial infections and increasing morbidity and mortality globally. This phenomenon, which occurs as a result of the ability of bacteria to adapt and evade conventional treatments, requires innovative strategies to address it. Artificial intelligence (AI) emerges as a transformative tool in this context, helping accelerate the identification of molecules with antimicrobial potential and optimize the design of new drugs. This article analyzes the usefulness of AI in antibiotic development, highlighting its benefits in terms of time, cost, and efficiency in the fight against resistant bacteria, as well as the challenges associated with its implementation in the biomedical field.
抗菌耐药性(AMR)是一个日益严重的公共卫生问题,使细菌感染的治疗复杂化,并在全球范围内增加发病率和死亡率。这种现象是由于细菌具有适应和规避传统治疗的能力而产生的,需要创新策略来应对。在这种背景下,人工智能(AI)成为一种变革性工具,有助于加速具有抗菌潜力分子的识别,并优化新药设计。本文分析了人工智能在抗生素研发中的作用,强调了其在对抗耐药细菌方面在时间、成本和效率方面的优势,以及在生物医学领域实施过程中面临的挑战。